AbbVie Sales And Growth Increasingly Dominated By Humira
This article was originally published in The Pink Sheet Daily
Executive Summary
Since its split from Abbott Laboratories in January, AbbVie has been telling a story of gradually overcoming loss of revenue due to generic-challenged lipid franchise via Humira growth and a promising pipeline. For the first quarter of 2013, Humira generated worldwide sales of $2.244 billion, slightly more than half of the company’s entire revenue base.
You may also be interested in...
Emerging Markets Earnings Roundup: Abbott, AbbVie, J&J, GSK (Part 3)
After Abbott/AbbVie split, emerging markets represent 40% of Abbott’s sales compared to 15% of AbbVie sales. Abbott, J&J and GSK report dismal sales in Europe, noting that EMs remain a bright spot.
Europe’s CHMP Okays Xtandi, Erivedge And Spedra, But Rejects Xeljanz
Two new cancer therapies – Astellas’ prostate cancer drug Xtandi and Roche’s basal cell carcinoma drug Erivedge – have been cleared for European approval by the CHMP scientific advisory panel. It also backed Vivus’ erectile dysfunction therapy Spedra and Avanir’s emotional outburst therapy, Nuedextra, but turned down Pfizer’s JAK inhibitor Xeljanz.
AbbVie CEO Emphasizes Humira Growth Plans, Potential Of HCV Program
AbbVie should appeal to long-term investors due to its sustainable business base and plan to issue and increase dividends over time, says CEO Richard Gonzalez.